Meredith A Barrett1, Olivier Humblet2, Justine E Marcus3, Kelly Henderson2, Ted Smith4, Nemr Eid5, J Wesley Sublett6, Andrew Renda7, LaQuandra Nesbitt8, David Van Sickle9, David Stempel2, James L Sublett6. 1. Propeller Health, San Francisco, California. Electronic address: meredith.barrett@propellerhealth.com. 2. Propeller Health, San Francisco, California. 3. University of Califronia, Berkeley, Berkeley, California. 4. Louisville Metro Government Department of Economic Growth and Innovation, Louisville, Kentucky. 5. Department of Pediatrics, University of Louisville School of Medicine, Louisville, Kentucky. 6. Family Allergy and Asthma, Louisville, Kentucky. 7. Humana Inc, Louisville, Kentucky. 8. Louisville Metro Public Health & Wellness, Louisville, Kentucky; University of Louisville School of Public Health and Information Sciences, Louisville, Kentucky. 9. Propeller Health, Madison, Wisconsin; Department of Population Health Sciences, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
Abstract
BACKGROUND: Asthma inflicts a significant health and economic burden in the United States. Self-management approaches to monitoring and treatment can be burdensome for patients. OBJECTIVE: To assess the effect of a digital health management program on asthma outcomes. METHODS:Residents of Louisville, Kentucky, with asthma were enrolled in a single-arm pilot study. Participants received electronic inhaler sensors that tracked the time, frequency, and location of short-acting β-agonist (SABA) use. After a 30-day baseline period during which reference medication use was recorded by the sensors, participants received access to a digital health intervention designed to enhance self-management. Changes in outcomes, including mean daily SABA use, symptom-free days, and asthma control status, were compared among the initial 30-day baseline period and all subsequent months of the intervention using mixed-model logistic regressions and χ2 tests. RESULTS: The mean number of SABA events per participant per day was 0.44 during the control period and 0.27 after the first month of the intervention, a 39% reduction. The percentage of symptom-free days was 77% during the baseline period and 86% after the first month, a 12% improvement. Improvement was observed throughout the study; each intervention month demonstrated significantly lower SABA use and higher symptom-free days than the baseline month (P < .001). Sixty-nine percent had well-controlled asthma during the baseline period, 67% during the first month of the intervention. Each intervention month demonstrated significantly higher percentages than the baseline month (P < .001), except for month 1 (P = .80). CONCLUSION: A digital health asthma management intervention demonstrated significant reductions in SABA use, increased number of symptom-free days, and improvements in asthma control. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02162576.
RCT Entities:
BACKGROUND: Asthma inflicts a significant health and economic burden in the United States. Self-management approaches to monitoring and treatment can be burdensome for patients. OBJECTIVE: To assess the effect of a digital health management program on asthma outcomes. METHODS: Residents of Louisville, Kentucky, with asthma were enrolled in a single-arm pilot study. Participants received electronic inhaler sensors that tracked the time, frequency, and location of short-acting β-agonist (SABA) use. After a 30-day baseline period during which reference medication use was recorded by the sensors, participants received access to a digital health intervention designed to enhance self-management. Changes in outcomes, including mean daily SABA use, symptom-free days, and asthma control status, were compared among the initial 30-day baseline period and all subsequent months of the intervention using mixed-model logistic regressions and χ2 tests. RESULTS: The mean number of SABA events per participant per day was 0.44 during the control period and 0.27 after the first month of the intervention, a 39% reduction. The percentage of symptom-free days was 77% during the baseline period and 86% after the first month, a 12% improvement. Improvement was observed throughout the study; each intervention month demonstrated significantly lower SABA use and higher symptom-free days than the baseline month (P < .001). Sixty-nine percent had well-controlled asthma during the baseline period, 67% during the first month of the intervention. Each intervention month demonstrated significantly higher percentages than the baseline month (P < .001), except for month 1 (P = .80). CONCLUSION: A digital health asthma management intervention demonstrated significant reductions in SABA use, increased number of symptom-free days, and improvements in asthma control. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02162576.
Authors: Barbara P Yawn; Gretchen M McCreary; John A Linnell; Cara B Pasquale; Elisha Malanga; Radmila Choate; David A Stempel; Rahul Gondalia; Leanne Kaye; Kathryn A Collison; Benjamin S Wu; Daniel Gratie; Richard H Stanford; Ryan Tomlinson Journal: Chronic Obstr Pulm Dis Date: 2021-10-28
Authors: Rajan Merchant; Stanley J Szefler; Bruce G Bender; Michael Tuffli; Meredith A Barrett; Rahul Gondalia; Leanne Kaye; David Van Sickle; David A Stempel Journal: World Allergy Organ J Date: 2018-12-03 Impact factor: 4.084
Authors: Jessica Chen; Leanne Kaye; Michael Tuffli; Meredith A Barrett; Shelanda Jones-Ford; Tina Shenouda; Rahul Gondalia; Kelly Henderson; Veronica Combs; David Van Sickle; David A Stempel Journal: JMIR Form Res Date: 2019-10-23
Authors: Elisa Fucà; Floriana Costanzo; Dimitri Bonutto; Annarita Moretti; Andrea Fini; Alberto Ferraiuolo; Stefano Vicari; Alberto Eugenio Tozzi Journal: Int J Environ Res Public Health Date: 2021-03-09 Impact factor: 3.390